The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Post Stabilisation Notice - GlaxoSmithKline

16 Oct 2019 09:43

RNS Number : 0559Q
Deutsche Bank AG London
16 October 2019
 

16-Oct-19

 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in

which such distribution would be unlawful.

 

GlaxoSmithKline Capital plc

Post-stabilisation Period Announcement

 

Further to the pre-stabilisation period announcement dated 16/09/20191 Deutsche Bank AG London (contact: DCM Syndication TA; telephone: 0207 54 54153 hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct Authority)2 was undertaken by the Stabilisation Manager(s)3 named below in relation to the offer of the following securities.

 

The Securities:

 

Issuer: GlaxoSmithKline Capital plc

 

Guarantor (if any): GlaxoSmithKline plc

 

Aggregate nominal amount: EUR 2.5bn

 

Description: GlaxoSmithKline EUR 2y FRN and 2/4y FXD

 

Stabilisation Manager(s): BNPP, CS, DB, MS

 

Offer Price: 100.650 / 100.289 / 100.184

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STACKADNFBDKOKD

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.